Zusammenfassung
Die Klassifikation auf der Grundlage der Krankheitskontrolle ermöglicht einen auf
den Patienten zugeschnittenen Zugang zur Asthmatherapie, der flexibel genug sein dürfte,
sich den Änderungen der Krankheitsaktivität im Verlauf anzupassen. Nach den aktuellen
Empfehlungen richtet sich die Behandlung des Asthmas nicht mehr nach dem Schweregrad,
sondern vielmehr nach der jeweiligen Asthmakontrolle. Dabei wird nicht mehr in Schweregraden,
sondern in therapeutischen Kategorien gedacht. Damit nähern sich die Empfehlungen
dem praktischen Umgang mit Asthmapatienten an und definieren mit dieser Vorgabe gleichzeitig
auch ein Therapieziel. Das Ziel der Asthmabehandlung ist das Erreichen und die Aufrechterhaltung
der klinischen Kontrolle („Kontrollstufe”), was bei der Mehrzahl der Patienten mithilfe
nicht-medikamentöser und pharmakologischer Maßnahmen im Rahmen einer Partnerschaft
zwischen Patient, Familie und behandelndem Arzt möglich ist. Gelingt die Kontrolle
der Erkrankung nach Einleitung der Therapie nicht und erreicht der Patient mit den
Maßnahmen keine oder nur eine partielle Kontrolle, sollte die Therapie intensiviert
(Eskalation) werden. Kann dagegen eine Kontrolle der Erkrankung hergestellt werden,
lässt sich die Medikation zurücknehmen, bis die minimal für die Kontrolle erforderliche
Therapie gefunden ist. Die aktuellen Empfehlungen werden der Dynamik des Asthmas besser
gerecht als die Empfehlungen auf der Basis von Schweregradeinteilungen und berücksichtigen
die individuellen Unterschiede zwischen Asthmatikern sowohl im Hinblick auf die Schwere,
die Variabilität als auch die Behandlung der Erkrankung.
Abstract
GINA together with many other national guidelines for the clinical management of asthma
recommend a disease severity assessment in order to determine the quantity and frequency
of medication. This classification scheme groups patients into one of four categories
(intermittent, mild-persistent, moderate-persistent, and severe-persistent). However,
it is important to recognise that asthma severity includes both severity of the underlying
disease and responsiveness to treatment. In addition, severity is not an unvarying
feature in any individual asthma patient and disease severity may change over months
or years. Thus, for ongoing asthma management, classification using the level of control
may be more relevant and useful in clinical practice. The new version of the GINA
guidelines 2006 recognises these limitations of severity assessment and classifies
the condition according to the level of control as “controlled”, “partly controlled”,
and “uncontrolled” asthma on the basis of daytime symptoms, restrictions of physical
activity, nocturnal symptoms/awakening, need for reliever/rescue medication, lung
function (PEF or FEV1) and the frequency of exacerbations. In addition, the patient
is assigned to one of five treatment “steps”. Each step represents treatment options
that are alternatives for controlling asthma. Moreover, steps 1 to 5 provide options
of increasing efficacy. In order to maintain asthma control regular monitoring and
adjustment is essential. In cases where asthma is not or only partially controlled
with the current treatment regimen, step-up treatment is recommended whereas disease
control allows a gradual stepping-down to the lowest possible dose of medication necessary
to maintain control. This novel asthma management approach based on disease control,
may facilitate acceptance and use of asthma guidelines in clinical practice.
Literatur
- 1
Wettengel R, Berdel D, Celga U. et al .
Empfehlungen der Deutschen Atemwegsliga zum Asthmamanagement bei Erwachsenen und bei
Kindern.
Med Klin.
1994;
89
57-67
- 2
Buhl R, Berdel D, Criée C P. et al .
Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma bronchiale 2005.
Pneumologie.
2006;
60
139-179
- 3
Boulet L P, Becker A, Bérubé D. et al .
The asthma consensus report 1999.
CMAJ.
1999;
161 (11 Suppl.)
S1-S6
- 4 Global Initiative for Asthma .GINA workshop report, global strategy for asthma management
and prevention. Available at: http//www.ginastma.org. Letzter Zugang 22. Dezember
2006
- 5 National Asthma Education and Prevention Program .(1997) Expert panel report 2:
guidelines for the diagnosis and management of asthma. National Institutes of Health.
Bethesda, MD: publication No. 97-4051
- 6
Wettengel R, Bredel D, Hofmann D. et al .
Empfehlungen zur Asthmatherapie von Kindern und Erwachsenen.
Pneumologie.
1998;
52
591-601
- 7
Crim C.
Clinical practice guidelines vesus actual clinical practice: the asthma paradigm.
Chest.
2000;
118 (2 Suppl)
62S-64S
- 8
Doerschug K C, Peterson M W, Dayton C S. et al .
Asthma guidelines: an assessment of physician understanding and practice.
Am J Respir Crit Care Med.
1999;
159
1735-1741
- 9
Freeman A C, Sweeney K.
Why general practitioners do not implement evidence: qualitative study.
BMJ.
2001;
323
1100-1102
- 10
Sawyer G, Miles J, Lewis S. et al .
Classification of asthma severity: should the international guidelines be changed?.
Clin Exp Allergy.
1998;
28
1565-1570
- 11
Vollmer W M, O’Hollaren M, Ettinger K M. et al .
Specialty differences in the management of asthma. A cross-sectional assessment of
allergists’ patients and generalists’ patients in a large HMO.
Arch Intern Med.
1997;
157
1201-1208
- 12
Graham L M.
Classifying asthma.
Chest.
2006;
130 (1 Suppl)
13S-20S
- 13
Miller M K, Johnson C, Miller D P. et al .
Severity assessment in asthma: An evolving concept.
J Allergy Clin Immunol.
2005;
116
990-995
- 14
Price D, Thomas M.
Breaking new ground: challenging existing asthma guidelines.
BMC Pulm Med.
2006;
6 (Suppl 1)
1-8
- 15
Kroegel C.
Vorschläge zur Systematisierung der nationalen Richtlinien für die Behandlung des
Asthma bronchiale im Erwachsenenalter in Deutschland.
Med Klinik.
1997;
92
621-625
- 16 Kroegel C. Asthma bronchiale. Pathogenetische Grundlagen, Diagnostik und Therapie. Stuttgart,
New York: Georg Thieme Verlag, 2. überarbeitete und erweiterte Auflage 2002
- 17 Kroegel C. Asthmatherapie - Leitfaden einer pathogenetisch begründeten Behandlung. Stuttgart-Steinen:
Zett Verlag, 2. überarbeitete und erweiterte Auflage 2005
- 18
Llewellin P, Sawyer G, Lewis S. et al .
The relationship between FEV1 and PEF in the assessment of the severity of airways obstruction.
Respirology.
2002;
7
333-337
- 19
Chipps B E.
Determinants of asthma and its clinical course.
Ann Allergy Asthma Immunol.
2004;
93
309-915
- 20
Kotaniemi-Syrjänen A, Reijonen T M, Korhonen K. et al .
Sodium cromoglycate therapy in wheezing infants: preliminary evidence of beneficial
outcome at early school age.
Pediatrics International.
2005;
47
627-634
- 21
Luskin A T.
What the asthma end points we know and love do and do not tell us. 9:.
J Allergy Clin Immunol.
2005;
115 (4 Suppl)
S539-545
- 22
Mutius E von.
Influences in allergy: epidemiology and the environment.
J Allergy Clin Immunol.
2004;
113
373-379
- 23
Rennard S I, Farmer S G.
Exacerbations and progression of disease in asthma and chronic obstructive pulmonary
disease.
Proc Am Thorac Soc.
2004;
1
88-92
- 24
Yawn B P, Molen T van der, Humbert M.
Asthma management: Are GINA guidelines appropriate for daily clinical practice?.
Prim Care Respir J.
2005;
14
294-302
- 25
Baker Jr K M, Brand D A, Hen J.
Classifying asthma: disagreement among specialists.
Chest.
2003;
124
2156-2163
- 26
Bateman E D, Boushey H A, Bousquet J. et al .
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL
study.
Am J Respir Crit Care Med.
2004;
170
836-844
- 27
Wenzel S E.
Severe asthma in adults.
Am J Respir Crit Care Med.
2005;
172
149-160
- 28
O’Byrne P M, Barnes P J, Rodriguez-Roisin R. et al .
Low-dose inhaled budesonide and formoterol in mild persistent asthma. the OPTIMA randomized
trial.
Am J Respir Crit Care Med.
2001;
164 (8 Pt 1)
1392-1397
- 29
Pauwels R A, Pedersen S, Busse W W. et al .
Early intervention with budesonide in mild persistent asthma: a randomized, double-blind
trial.
Lancet.
2003;
361 (9363)
1071-1076
- 30
Zeiger R S, Baker J W, Kaplan M S. et al .
Variability of symptoms in mild persistent asthma: baseline data from the MIAMI study.
Respir Med.
2004;
98
898-905
- 31
Using beta2-stimulants in asthma.
Drug Ther Bull.
1997;
35
1-4
- 32
Godfrey S, Bar-YIshay E.
Exercised-induced asthma revisited.
Respir Med.
1993;
87
331-344
- 33
Leff J A, Busse W W, Pearlman D. et al .
Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and
exercise-induced bronchoconstriction.
N Engl J Med.
1998;
339
147-152
- 34
Spooner C H, Saunders L D, Rowe B H.
Nedocromil sodium for preventing exercise-induced bronchoconstriction.
Cochrane Database Syst Rev.
2000;
(2)
CD 001183
- 35
Ram F S, Robinson S M, Black P N.
Physical training for asthma.
Cochrane Database Syst Rev.
2000;
(2)
CD 001116
- 36
Reiff D B, Choudry N B, Pride N B. et al .
The effect of prolonged submaximal warm-up exercise on exercise-induced asthma.
Am Rev Respir Dis.
1989;
139
479-484
- 37
Adams N P, Bestall J B, Malouf R. et al .
Inhaled beclomethasone versus placebo for chronic asthma.
Cochrane Database Syst Rev.
2005;
(1)
CD002738
- 38
Kroegel C, Reißig A, Walter R. et al .
Inhalierbare Glucocorticoide der dritten Generation.
Ciclesonid Arzneimittelth.
2006;
24
73-83
- 39
Barnes N C, Miller C J.
Effect of leucotriene receptor antagonist therapy on the risk of asthma exacerbations
in patients with mild to moderate asthma: an integrated analysis of zifirlukast trials.
Thorax.
2000;
55
478-483
- 40
Bleeker E R, Welch M J, Weinstein S F. et al .
Low-dose inhaled fluticasone pr opionate versus oral zafirlukast in the treatment
of persistent asthma.
J Allergy Clin Immunol.
2000;
105 (6 Pt 1)
1123-1129
- 41
Drazen J M, Isreal E, O’Byrne P M.
Treatment of asthma with drugs modifying the leukotriene pathway.
N Engl J Med.
1999;
340
197-206
- 42
Philip G, Nayak A S, Berger W E. et al .
The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal
allergic rhinitis.
Curr Med Res Opin.
2004;
20
1549-1558
- 43
Wilson A M, Dempsey O J, Sims E J. et al .
A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis
and asthma.
Clin Exp Allergy.
2001;
31
616-624
- 44
Kidney J, Dominguez M, Taylor P M. et al .
Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy.
Am J Respir Crit Care Med.
1995;
151
1907-1914
- 45
Tasche M J, Wouiden J C van der, Uijen J H. et al .
Randomised placebo-controlled trial of inhaled sodium cromoglycate in 1 - 4-year-old
children with moderate asthma.
Lancet.
1997;
350 (9084)
1060-1064
- 46
Tsiu S J, Self T H;.
Theophylline toxicity: update.
Ann Allergy.
1990;
64 (2 Pt 2)
241-257
- 47
Lazarus S C, Boushey H A, Fahy J V. et al .
Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids
in patients with persistent asthma: a randomized controlled trial.
JAMA.
2001;
285
2583-2593
- 48
Lemanske Jr R F, Sorkness C, Mauger E A. et al .
Inhaled corticosteroid reduction and elimination in patients with persistent asthma
receiving salmeterol: a randomized controlled trial.
JAMA.
2001;
285
2594-2603
- 49
Woolcock A, Lundback B, Ringdal N. et al .
Comparison of addition of salmeterol to inhaled steroids with doubling of the dose
of inhaled steroids.
Am J Respir Crit Care Med.
1996;
153
1481-1488
- 50
Pauwels R A, Lofdahl C G, Postma D S. et al .
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol
and Corticosteroids Establishing Therapy (FACET) International Study Group.
N Engl J Med.
1997;
337
1405-1411
- 51
Powell H, Gibson P G.
Inhaled corticosteroid doses in asthma: an evidence-based approach.
Med J Aust.
2003;
178
223-225
- 52
Cates C J, Adams N, Bestall J.
Holding chambers versus nebulisers for inhaled steroids in chronic asthma.
Cochrane Database Syst Rev.
2001;
(2)
CD001491
- 53
Price D B, Hernandez D, Magyar P. et al .
Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT)
International Study Group. Randomised controlled trial of montelukast plus inhaled
budesonide versus double dose inhaled budesonide in adult patients with asthma.
Thorax.
2003;
58
211-216
- 54
Evans D J, Taylor D A, Zetterstrom O. et al .
A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled
budesonide for moderate asthma.
N Engl J Med.
1997;
337
1412-1418
- 55
Malone R, LaForce C, Nimmagadda S. et al .
The safety of twice-daily treatment with fluticasone propionate and salmeterol in
pediatric patients with persistent asthma.
Ann Allergy Asthma Immunol.
2005;
95
66-71
- 56
Toogood J H, Baskerville J C, Jennings B. et al .
Influence of dosing frequency and schedule on the response of chronic asthmatics to
the aerosol steroid budesonide.
J Allergy Immunol.
1982;
70
288-298
- 57
Vaquerizo M J, Casan P, Castillo J. et al .
Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma.
Thorax.
2003;
58
204-210
- 58
Mash B, Bheekie A, Jones P W.
Inhaled vs. oral steroids for adults with chronic asthma.
Cochrane Databse Syst Rev.
2000;
2
CD 002160
- 59
Ayres J G, Jyothish D, Ninan T.
Brittle asthma.
Paediatr Respir Rev.
2004;
5
40-44
- 60 Kroegel C, Foerster M. Omalizumab. In: “Handbook of Therapeutic Antibodies”, Dübel
S. (Hrsg.), 1. Auflage. Weinheim: Wiley-VCH 2007 Volume III: S. 534-583
- 61
Bergmann N, Foerster M, Reissig A. et al .
Benefits of Interferon-acon-1 (IFN-acon-1) as add-on therapy in patients with severe
persistent asthma who are inadequately controlled despite best available therapy.
Results of a 12-month prospective case-controlled study.
Eur Resp J.
2006;
28 (Suppl 50)
439s
- 62
Berry M A, Hargadon B, Shelley M. et al .
Evidence of a role of tumor necrosis factor in refractory asthma.
N Engl J Med.
2006;
354
697-708
- 63
Erin E M, Leaker B R, Nicholson G C. et al .
The effects of a monoclonal antibody directed against tumor necrosis factor-alpha
in asthma.
Am J Respir Crit Care Med.
2006;
174
753-762
- 64
Howarth P H, Babu K S, Arshad H S. et al .
Tumour necrosis factor (TNF) as a novel therapeutic target in symptomatic corticosteroid
dependent asthma.
Thorax.
2005;
60
1012-1018
- 65
Kroegel C, Bergmann N, Foerster M. et al .
Interferon-acon-1 treatment of three patients with severe glucocorticoid-dependent
asthma. Effect on disease control and systemic glucocorticosteroid dose.
Respiration.
2006;
73
566-570
- 66
Mock B, Kroegel C, Kugler J.
Interferon-alpha treatment in severe persistent bronchial asthma: a meta-analysis.
Thorax.
in Druck
- 67
Reddel H K, Barnes D J.
Exacerbation Advisory Panel. Pharmacological strategies for self-management of asthma
exacerbations.
Eur Respir J.
2006;
28
182-199
- 68
Bateman E D, Fairall L, Lombardi D M. et al .
Budesonide/formoterol and formoterol provide similar rapid relief in patients with
acute asthma showing refractoriness to salbutamol.
Respir Res.
2006;
7
13
- 69
Nicholson K G, Nguyen-Van-Tam J S, Ahmed A H. et al .
Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine
on pulmonary function in asthma.
Lancet.
1998;
351 (9099)
326-331
- 70
Hawkins G, McMahon A D, Twaddle S. et al .
Stepping down inhaled corticosteroids in asthma: randomised controlled trial.
BMJ.
2003;
326 (7399)
1115-1118
- 71
Boulet L P, Drollmann A, Magyar P. et al .
Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of
persistent asthma.
Respir Med.
2006;
100
785-794
- 72
Masoli M, Weatherall M, Holt S. et al .
Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled
corticosteroids in symptomatic asthma.
Thorax.
2005;
60
730-734
- 73
Rabe K F, Atienza T, Magyar P. et al .
Effect of budesonide in combination with formoterol for reliever therapy in asthma
exacerbations: a randomised controlled, double-blind study.
Lancet.
2006;
368 (9537)
744-753
- 74
Rabe K F, Pizzichini E, Stallberg B. et al .
Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate
asthma: a randomized, double-blind trial.
Chest.
2006;
129
246-256
Prof. Dr. med. Dr. rer. nat. Claus Kroegel
Pneumologie und Allergologie/Immunologie, Medizinische Klinik I, Friedrich-Schiller-Universität
Erlanger Allee 101
7740 Jena
eMail: claus.kroegel@med.uni-jena.de
